Corbus Pharmaceuticals Holdings, Inc. – LSE:0SZI.L

Founder-led company

Corbus Pharmaceuticals Holdings stock price today

$0.651
-11.91
-94.82%
Financial Health
0
1
2
3
4
5
6
7
8
9

Corbus Pharmaceuticals Holdings stock price monthly change

-78.72%
month

Corbus Pharmaceuticals Holdings stock price quarterly change

-78.72%
quarter

Corbus Pharmaceuticals Holdings stock price yearly change

+116.72%
year

Corbus Pharmaceuticals Holdings key metrics

Market Cap
 159.42M
Enterprise value
 N/A
P/E
 N/A
EV/Sales
 N/A
EV/EBITDA
 N/A
Price/Sales
 N/A
Price/Book
 N/A
PEG ratio
 N/A
EPS
 -6.96
Revenue
 N/A
EBITDA
 -36.72M
Income
 -33.75M
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 N/A

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Corbus Pharmaceuticals Holdings stock price history

Corbus Pharmaceuticals Holdings stock forecast

Corbus Pharmaceuticals Holdings financial statements

Profit Margin

Corbus Pharmaceuticals Holdings, Inc. (LSE:0SZI.L): Profit margin
Jun 2023 0 -8.78M
Sep 2023 0 -10.05M
Dec 2023 1.34M -8.02M -594.27%
Mar 2024 0 -6.89M
0SZI.L income statement history

Corbus Pharmaceuticals Holdings Financials Estimate

Corbus Pharmaceuticals Holdings, Inc. (LSE:0SZI.L): Analyst Estimates
Dec 2023 1.34M -8.02M -594.27%
Mar 2024 0 -6.89M
Oct 2025 0 -9.39M
Dec 2025 0 -9.84M

  • Analysts Price target

  • Financials & Ratios estimates

Show more

Debt to Assets

Corbus Pharmaceuticals Holdings, Inc. (LSE:0SZI.L): Debt to assets
Jun 2023 43723383 34.20M 78.23%
Sep 2023 36283405 35.97M 99.14%
Dec 2023 28272393 35.17M 124.42%
Mar 2024 125744162 28.77M 22.89%
0SZI.L balance sheet history

Cash Flow

Corbus Pharmaceuticals Holdings, Inc. (LSE:0SZI.L): Cash Flow
Jun 2023 -7.80M 8.80M 17.68K
Sep 2023 -7.17M 10.89M -820.50K
Dec 2023 -6.00M 10.38M -1.90M
Mar 2024 -7.96M -98.23M 106.58M
0SZI.L cash flow history

Corbus Pharmaceuticals Holdings alternative data

Corbus Pharmaceuticals Holdings
Employees

Corbus Pharmaceuticals Holdings, Inc. (LSE:0SZI.L): Employee count
Aug 2023 33
Sep 2023 33
Oct 2023 33
Nov 2023 33
Dec 2023 33
Jan 2024 33
Feb 2024 33
Mar 2024 33
Apr 2024 33
May 2024 33
Jun 2024 19
Jul 2024 19

Corbus Pharmaceuticals Holdings other data

Corbus Pharmaceuticals Holdings
Executives

Insider Compensation
Dr. Yuval Cohen (1975) Chief Executive Officer & Director $810,550
Dr. Barbara White (1950) Head of Research & Chief Medical Officer $570,700
Mr. Sean F. Moran CPA, M.B.A., CPA, MBA (1958) Chief Financial Officer
 $520,000
Mr. Craig Stuart Millian M.B.A. Chief Commercial Officer
Ted Jenkins Senior Director of Investor Relations & Corporation Communications
Scott Constantine Senior Director & Head of Clinical Operations
Sergei Atamas Executive Director of Research
Dr. Mark A. Tepper Co-Founder & Consultant

Frequently Asked Questions (FAQ)

  • What's the price of Corbus Pharmaceuticals Holdings stock today?

    One share of Corbus Pharmaceuticals Holdings stock can currently be purchased for approximately $0.65.

  • When is Corbus Pharmaceuticals Holdings's next earnings date?

    Unfortunately, Corbus Pharmaceuticals Holdings's (0SZI.L) next earnings date is currently unknown.

  • Does Corbus Pharmaceuticals Holdings pay dividends?

    No, Corbus Pharmaceuticals Holdings does not pay dividends.

  • How much money does Corbus Pharmaceuticals Holdings make?

    Corbus Pharmaceuticals Holdings has a market capitalization of 159.42M.

  • What is Corbus Pharmaceuticals Holdings's stock symbol?

    Corbus Pharmaceuticals Holdings, Inc. is traded on the LSE under the ticker symbol "0SZI.L".

  • What is Corbus Pharmaceuticals Holdings's primary industry?

    Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.

  • How do i buy shares of Corbus Pharmaceuticals Holdings?

    Shares of Corbus Pharmaceuticals Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Corbus Pharmaceuticals Holdings's key executives?

    Corbus Pharmaceuticals Holdings's management team includes the following people:

    • Dr. Yuval Cohen Chief Executive Officer & Director(age: 50, pay: $810,550)
    • Dr. Barbara White Head of Research & Chief Medical Officer(age: 75, pay: $570,700)
    • Mr. Sean F. Moran CPA, M.B.A., CPA, MBA Chief Financial Officer(age: 67, pay: $520,000)
    • Mr. Craig Stuart Millian M.B.A. Chief Commercial Officer
    • Ted Jenkins Senior Director of Investor Relations & Corporation Communications
    • Scott Constantine Senior Director & Head of Clinical Operations
    • Sergei Atamas Executive Director of Research
    • Dr. Mark A. Tepper Co-Founder & Consultant

  • Is Corbus Pharmaceuticals Holdings founder-led company?

    Yes, Corbus Pharmaceuticals Holdings is a company led by its founder Dr. Mark A. Tepper.

  • How many employees does Corbus Pharmaceuticals Holdings have?

    As Jul 2024, Corbus Pharmaceuticals Holdings employs 19 workers, which is 42% less then previous quarter.

  • When Corbus Pharmaceuticals Holdings went public?

    Corbus Pharmaceuticals Holdings, Inc. is publicly traded company for more then 6 years since IPO on 23 Nov 2018.

  • What is Corbus Pharmaceuticals Holdings's official website?

    The official website for Corbus Pharmaceuticals Holdings is corbuspharma.com.

  • Where are Corbus Pharmaceuticals Holdings's headquarters?

    Corbus Pharmaceuticals Holdings is headquartered at 500 River Ridge Drive, Norwood, MA.

  • How can i contact Corbus Pharmaceuticals Holdings?

    Corbus Pharmaceuticals Holdings's mailing address is 500 River Ridge Drive, Norwood, MA and company can be reached via phone at +61 79630100.

Corbus Pharmaceuticals Holdings company profile:

Corbus Pharmaceuticals Holdings, Inc.

corbuspharma.com
Exchange:

LSE

Full time employees:

19

Industry:

Medical - Pharmaceuticals

Sector:

Healthcare

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

+61 79630100
500 River Ridge Drive
Norwood, MA 02062

:
ISIN: US21833P3010
CUSIP: 21833P301